Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Apollohosp Ltd — Q4 FY24
Apollo Hospitals reported a strong Q4 FY24 with consolidated revenue of INR 4,944 crore (up 15% YoY) and EBITDA of INR 641 crore (up 31% YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Apollo Hospitals reported a strong Q4 FY24 with consolidated revenue of INR 4,944 crore (up 15% YoY) and EBITDA of INR 641 crore (up 31% YoY). Healthcare services revenue grew 17% YoY, driven by 6.1% IP volume growth and 12% ARPOB increase to INR 59,523. Occupancy stood at 65%, with metro hospitals above 70%. The company added 150 new doctors, which temporarily impacted healthcare services margins (23.1%), but management expects a 150 bps margin expansion in FY25. Apollo 24/7 achieved positive EBITDA of INR 12 crore, with a target to breakeven in 6-8 quarters. Pharmacy distribution growth was impacted by inventory rationalization. Guidance includes 15%+ healthcare services growth, 50% GMV growth for Apollo 24/7, and 500-550 new pharmacy stores. Risk: New hospital ramp-up and doctor hiring may delay margin recovery.
अपोलो हॉस्पिटल्स ने चौथी तिमाही में अच्छा प्रदर्शन किया। कुल कमाई 4,944 करोड़ रुपये रही, जो पिछले साल से 15% ज्यादा है। कमाई पर मुनाफा (EBITDA) 641 करोड़ रुपये रहा, जो 31% बढ़ा। अस्पताल सेवाओं की कमाई 17% बढ़ी, क्योंकि मरीजों की संख्या 6.1% और प्रति मरीज खर्च 12% बढ़कर 59,523 रुपये हो गया। 65% बिस्तर भरे रहे, बड़े शहरों में 70% से ज्यादा। 150 नए डॉक्टर जुड़ने से मुनाफा मार्जिन 23.1% रहा, लेकिन अगले साल इसमें 1.5% सुधार की उम्मीद है। अपोलो 24/7 ने 12 करोड़ रुपये का मुनाफा कमाया और 6-8 तिमाहियों में बराबर होने का लक्ष्य है। फार्मेसी की बिक्री स्टॉक कम करने से प्रभावित हुई। आगे अस्पताल सेवाओं में 15% से ज्यादा, अपोलो 24/7 में 50% और 500-550 नई फार्मेसियों की योजना है। जोखिम: नए अस्पताल और डॉक्टरों की भर्ती से मुनाफा सुधार में देरी हो सकती है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
New hospital ramp-up may delay margin recovery
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Occupancy
65%
flat YoY
Group occupancy remained at 65% despite ALOS reduction and bed recalibration; metro hospitals above 70%.
ARPOB
INR 59,523
+12% YoY
Average revenue per occupied bed increased 12% year-on-year, driven by better case mix and payer mix.
Apollo 24/7 GMV
INR 681 crore
+35% YoY
Digital platform GMV grew 35% YoY; 2 million new users added in Q4.
New Pharmacy Stores Added (FY24)
489
-56% YoY
Net addition of 489 pharmacies in FY24 vs 1,100 in FY23, due to inventory rationalization.
What Changed vs Last Quarter
NEW
Healthcare services EBITDA margin expansion of 150 bps in FY25
Targeting 25% margin by end of FY25 through cost optimization and surgical volume growth.
NEW
Add 500-550 new pharmacy stores in FY25
Offline pharmacy network expansion to continue at similar pace as FY24.
UPDATED
Healthcare services revenue growth >15% in FY25
Driven by volume growth, network expansion, and better asset utilization.
UPDATED
Apollo 24/7 breakeven in 6-8 quarters
Targeting GMV of INR 1,700 crore per quarter and take rate improvement from 4% to 8%.
DROPPED
200 bps margin improvement in healthcare services over next few quarters
Internal target to increase EBITDA margins by 200 basis points through volume growth, clinical program expansion, and cost rationalization.
DROPPED
2,000 beds over four years at INR 3,000 crore capex
Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.
NEW RISK
New hospital ramp-up may delay margin recovery
Four new hospitals with 1,500 beds to be operationalized by calendar 2025-26; initial costs could pressure margins.
NEW RISK
Doctor hiring costs may not yield immediate volume benefits
150 new doctors hired in FY24; full revenue contribution expected only by Q2 FY25, posing near-term margin risk.
NEW RISK
Inventory rationalization impact on pharmacy distribution
Lower inventory buildup reduced pharmacy distribution sales by ~INR 150 crore in Q4; growth recovery depends on store-level execution.
NEW RISK
Competitive pressure in Nashik market
Nashik hospital remains a drag on western region occupancy due to multiple competitors and low-paying patient mix.
RISK GONE
Margin pressure from new bed additions
New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.
RISK GONE
Seasonality and one-off events impacting growth
Q3 saw lower elective surgeries due to holidays and Chennai cyclone, affecting revenue mix and margins. Similar events could recur.
RISK GONE
Slowdown in 24/7 daily active users
Despite adding 2 million new users, daily active users declined sequentially, raising concerns about user engagement and monetization.
RISK GONE
Regulatory risk from kidney racket allegations
Allegations of involvement in a kidney racket could impact reputation, though management states no negative findings have been made.
🤫 Topics management stopped discussing
Mentioned in Q2 FY24, Q3 FY24
Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.
Mentioned in Q1 FY24, Q2 FY24
Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher.
Mentioned in Q1 FY24, Q3 FY24
New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.
Fast read
Guidance and risk preview
Driven by volume growth, network expansion, and better asset utilization.
Four new hospitals with 1,500 beds to be operationalized by calendar 2025-26; initial costs could pressure margins.
View Risks →